Reply: SUN vs BEV\+IFN in first-line mRCC therapy: No evidence for a statistically significant difference in progression-free survival

J. S Thompson Coon, Z. Liu, M. Hoyle, G. Rogers, C. Green, T. Moxham, K. Welch, K. Stein

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)234-235
Number of pages2
JournalBritish Journal of Cancer
Issue number1
Publication statusPublished - Jan 2010
Externally publishedYes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this